Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$2003.00
-9.00 (-0.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.0B · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.0%
↓Gross Margin
27.3%
↓Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.9%
FCF CAGR
—
FCF margin
-10.6%
FCF / Net income
1.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $60.56B · net income $-3.29B · FCF $-6.40B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $60.56B | $60.56B | $55.41B | $51.02B | $49.63B |
| Net Income | $-3.29B | $-3.29B | $1.38B | $1.60B | $1.48B |
| EBITDA | $-2.46B | $-2.46B | $4.20B | $4.86B | $4.65B |
| EPS | -384.95 | -384.95 | 159.98 | 183.07 | 169.09 |
| Gross Margin | 27.3% | 27.3% | 25.0% | 26.9% | 27.0% |
| Operating Margin | 6.8% | 6.8% | 3.5% | 4.3% | 3.9% |
| Net Margin | -5.4% | -5.4% | 2.5% | 3.1% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.37 | 0.35 | 0.35 |
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.40B | $-6.40B | $-2.96B | $1.28B | $2.01B |
| Returns | |||||
| ROE | -10.0% | -10.0% | 3.8% | 4.5% | 4.3% |
| Valuation | |||||
| P/E | — | — | 13.60 | 10.73 | 12.68 |
| EV/EBITDA | — | — | 6.50 | 4.50 | 5.07 |
| P/B | 0.52 | 0.52 | 0.51 | 0.48 | 0.54 |
| Growth & Yield | |||||
| Revenue Growth | 9.3% | 9.3% | 8.6% | 2.8% | — |
| EPS Growth | -340.6% | -340.6% | -12.6% | 8.3% | — |
| Dividend Yield | 4.5% | 4.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.4%
Start / end P/E
n/dx → n/dx
EPS bridge
159.98 → -384.95
Residual
-10.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.